menu

FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents

close
FDA Requires New Class Warnings for All Gadolinium-Based Contrast Agents
RestartResume
Choose a format
Media formats available:
Details
Comments
  • Overview

    The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.

    Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch.

    A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety

    Released 12/19/2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs.

    Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch.

    A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety

    Released 12/19/2017

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 1/20/20